The FDA’s Roadmap to reducing animal testing in preclinical studies (April, 2025) sets out an ambitious and clear objective “to make animal studies the exception rather than the norm for preclinical safety/toxicity testing” within 3-5 years from now. Existing in silico tools can give early risk assessments of common safety issues to help reduce reliance on animal studies and contribute to this objective.

In this webinar, we introduce ToxStudio®, a suite of in silico tools addressing critical preclinical safety challenges:

• Libra™ – AI-powered DILI prediction
• Cardiac Safety Simulator™ – Modeling and simulation platform to predict QT/proarrhythmia risk
• Secondary Intelligence™ – Secondary pharmacology software to contextualize and categorize off-target risks

ToxStudio is part of Certara’s Non-Animal Navigator™ solution designed to help biopharmaceutical companies lead the shift toward adopting New Approach Methodologies (NAMs) outlined in the FDA roadmap.